Longeveron
1 known investors
Longeveron develops allogeneic cell therapies targeting life-threatening conditions in vulnerable populations, particularly children and the elderly. The company's lead candidate, Lomecel-B, is being evaluated for conditions including hypoplastic left heart syndrome, pediatric cardiomyopathy, Alzheimer's disease, and age-related frailty.
BiotechLongevityMedical Devices
Investors · 1
In the news
- Top Longevity Biotech Startups by Fundraising (2026) – New Market Pitchnewmarketpitch.com · 2026
- Longeveron Q1 2026 results and cash runway | LGVN Quarterly Report (10-Q)stocktitan.net · 2026
- Longeveron Announces 2025 Full Year Financial Results and Provides Business Updatefinance.yahoo.com · 2026
- Longeveron raises $15.9M in private placement | LGVN SEC Filing - Form 8-Kstocktitan.net · 2026
- Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offeringglobenewswire.com